ABOUT THE JOURNAL
Aims and scope of journal |Impact factor |
Abstracted/indexed in |
ISSN and eISSN |
Editors |
Top of page
Aims and scope of journal
Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original articles, letters and communications in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.
Commentaries and Point-Counterpoint provide a forum for perspectives in clinical pharmacology and therapeutics in the context of contemporary scientific, political, economic and social issues. State of the Art contributions summarize the latest advances in the science underpinning drug discovery, development, regulation and utilization. CPT highlights issues transforming the practice of clinical pharmacology, including ethics, education and public policy. Bench-to-bedside translation in therapeutics is presented in the context of clinical applications of basic pharmacology, discovery and translational medicine, and drug development.
Top of pageImpact Factor
ISI 2006 Impact Factor: 8.066*
Rank:
6/199 Pharmacology
*Journal Citation Reports, Thomson, 2007
Top of pageAbstracted/indexed in
Biological Abstracts, ISI
Biosis Previews, ISI
Chemical Abstracts, CAS
Current Contents, ISI
Derwent Biotechnology Abstracts, Ovid
EMBASE, Elsevier
Index to Scientific Reviews, ISI
Inpharma Weekly, Ovid
International Pharmaceutical Abstracts, Ovid
MEDLINEŽ
Nutrition Abstracts, CABI
Nutrition Research Newsletter, Insight
Personal Alert, ISI
Pharmacoeconomics and Outcomes News, Adis
Protozoological Abstracts, CABI
Reactions Weekly, Ovid
Review of Aromatic and Medicinal Plants, CABI
Review of Medical and Veterinary Mycologym, CABI
Science Citation Index, ISI
Scopus, Elsevier
Tropical Diseases Bulletin, CABI
ISSN and eISSN
The international standard serial number (ISSN) for Clinical Pharmacology & Therapeutics is 0009-9236 and the electronic standard serial number (eISSN) is 1532-6535.
Top of pageEditors
Scott Waldman, MD, PhD, FCP
Dr. Waldman is the Samuel MV Hamilton Endowed Professor of Medicine, the Chair of the Department of Pharmacology and Experimental Therapeutics, the Director of the Division of Clinical Pharmacology, and the Director of the Developmental Therapeutics program of the Kimmel Cancer Center at Thomas Jefferson University. He is a past president of ASCPT and served on its Board of Directors. Dr. Waldman holds an MD from Stanford University and a PhD from Thomas Jefferson University. He is a leading clinician investigator whose extensive research spans the pharmacology spectrum from molecular biology of signal transduction to novel diagnostics and therapeutics for cancer. His studies have resulted in more than 130 publications and have produced more than 45 awarded patents and patent applications worldwide.
Andre Terzic, MD, PhD
Dr. Terzic is a Professor of Medicine and Molecular Pharmacology and Experimental Therapeutics at the Mayo Clinic College of Medicine. He is a Mayo Foundation Endowed Career Scientist and program co-Director for the Postgraduate Cardiovascular Fellowship Program at the Mayo Graduate School of Medicine. Dr. Terzic received his MD from the School of Medicine at the University of Belgrade and continued his education at the University of Illinois, receiving a PhD in pharmacology. He is a past president of ASCPT and is active in many roles at the Mayo Clinic including Vice-Chairman of the Department of Cardiovascular Research and Director of the Cardiovascular Research Laboratory and the NIH Cardiovascular Training Program in Cardiovasology. Dr. Terzic is a widely published author and educator in the field of pharmacology.
Arthur J. Atkinson, MD
Dr. Atkinson received his Bachelor of Arts degree in chemistry from Harvard College and his MD from Cornell University Medical College. After initiating the clinical pharmacology program at Northwestern University Medical School, Dr. Atkinson pursued such notable positions as Corporate Vice President for Clinical Development and Medical Affairs at the Upjohn Company and Adjunct Professor in the Center for Drug Development Science at Georgetown University. He was later appointed Senior Advisor in Clinical Pharmacology to the Director of the NIH Clinical Center. Dr. Atkinson is a Master of the American College of Physicians and has served as president for the American Board of Clinical Pharmacology and ASCPT. He has contributed to many professional societies as an editorial board member and is extensively published in the field of pharmacology.
Christine Haller, MD
Director of Global Safety at Amgen, is board certified in Clinical Pathology and Medical Toxicology. Widely published in scientific journals such as the New England Journal of Medicine and Clinical Pharmacology and Therapeutics, Dr. Haller's early research focused on the safety of dietary supplements used for weight loss and athletic performance while a faculty member in the Division of Clinical Pharmacology and Experimental Therapeutics at the UCSF School of Medicine. Her current work involves risk assessment and other safety aspects of early clinical drug development at Amgen. An active member of the American Society for Clinical Pharmacology and Therapeutics, Dr. Haller is the Vice Chair of the Therapeutic Drug and Toxicology Monitoring Scientific Section and served on the Scientific Program Committee from 2004 until 2006.
Raymond J. Hohl, MD, PhD
Dr. Hohl is the Holden Family Chair, Professor of Internal Medicine and Pharmacology, Associate Chair in the Department of Internal Medicine, Associate Director for Translational Research in the Holden Comprehensive Cancer Center. He received his Ph.D. in Pharmacology from Rush University. He is a Diplomate of the American Board of Internal Medicine, a Fellow at the American College of Physicians and has been recognized with such honors as the PMA Faculty Development Award in Clinical Pharmacology and the Laureate Award from the Iowa Chapter of the American College of Physicians. Dr. Hohl earned his MD at Rush Medical College. His clinical research interests focus on the evaluation of the potential role for pharmacologic inhibitors of this biosynthetic pathway in the treatment of various hematologic malignancies and solid tumors.
Peter K. Honig, MD, MPH
Dr. Honig is the Executive Vice President of Worldwide Regulatory Affairs and Product Safety for Merck Research Laboratories. After receiving his baccalaureate, medical and public health degrees from Columbia University, he joined the Food and Drug Administration as a medical review officer in the Division of Pulmonary and Allergy Drug Products. Dr. Honig is a Fellow of the American College of Physicians and a past president of ASCPT.
Shiew-Mei Huang, PhD
Dr. Huang is the Deputy Office Director for Science in the Office of Clinical Pharmacology at the Food and Drug Administration's Center for Drug Evaluation and Research. She is an American Association of Pharmaceutical Scientists Fellow and Diplomate of the American Board of Clinical Pharmacology. Dr. Huang oversees several external research projects on drug metabolism, pharmacogenetics and clinical QT evaluations. She has published more than 90 peer-reviewed articles and book chapters with a focus on clinical pharmacology, drug metabolism and biopharmaceutics.
Gregory L. Kearns, PharmD, PhD
Dr. Kearns is Chairman of Pediatric Medical Research at the Children's Mercy Hospital and the Marion Merrell Dow/Missouri Chair in Pediatric Medical Research at the University of Missouri-Kansas City School of Medicine. He received his Bachelor of Science degree from the St. Louis College of Pharmacy and his PharmD from the University of Cincinnati. Dr. Kearns continued his education, earning a PhD in Medicine and Clinical Pharmacology from Erasmus University. Dr. Kearns has received the Distinguished Investigator Award from the American College of Clinical Pharmacology and is a recipient of the Roy Patterson Distinguished Lectureship from the American Academy of Allergy, Asthma and Clinical Immunology. He is widely published and is a past president of ASCPT.
Richard L. Lalonde, PharmD
Dr. Lalonde is Vice President and Global Head of Clinical Pharmacology at Pfizer. He has been elected as a Fellow of the American College of Clinical Pharmacology, the American Association of Pharmaceutical Scientists and the American College of Clinical Pharmacy. He is the Chair of the Pharmacokinetics, Pharmacodynamics, and Pharmacometrics Section of ASCPT. Dr. Lalonde's research over the past 27 years has been focused on the application of pharmacokinetic and pharmacodynamic principles to the optimal utilization of drugs in patients. More recently he has been a leader in the application of novel modeling and simulation methods to improve clinical trial designs and drug development. Dr. Lalonde is a graduate of the University of Minnesota (Pharm.D.) and the University of Toronto (B.Sc. Pharmacy).
Micheline Piquette-Miller, PhD
Dr. Piquette-Miller is an Associate Professor and Director of the Division of Pharmaceutical Sciences at the University of Toronto. She received her BSc and PhD in Pharmaceutical Sciences from the University of Alberta and continued her postdoctoral research studies at the Department of Biopharmaceutical and Molecular Pharmacology at the University of California, San Francisco. Dr. Piquette-Miller is the President of the Canadian Society of Clinical Pharmacology and has served on the Board of Directors and Chair of the Pharmacogenetics and Molecular Pharmacology Section for ASCPT. She has been the recipient of numerous awards and honors for her research in the areas of drug transport and multidrug resistance including the 2006 Leon I. Goldberg Young Investigator Award from ASCPT.
Brian Smith, PhD
Dr. Smith, a Biostatistics Senior Manager at Amgen Inc., applies statistical methods to analyze early clinical research. Graduating from the University of Kentucky with a PhD in Statistics, Dr. Smith led the group of Clinical Pharmacology and Pharmacokinetic Statisticians at Eli Lilly and Company and eventually the Internal Medicine Program Phase Statistics and Oncology, Cardiovascular, Muskoskeletal Program Phase Statistics groups, assessing data from Phase I and II studies and evaluating statistician and programmer performance. The author of 16 published works and more than 20 oral presentations, Dr. Smith has contributed to the boards, committees, and working groups of professional associations such as the PhRMA Foundation and the American Society for Clinical Pharmacology and Therapeutics.
Rachel Tyndale, PhD
Dr. Tyndale is the Canada Research Chair in Pharmacogenetics at the University of Toronto and Director of Pharmacogenetics for the Centre for Addiction and Mental Health. Internationally recognized for breakthrough discoveries in mental health, brain dysfunction, and neurodegenerative disorders, Dr. Tyndale's research will continue to power innovative drug treatments and the personalization of medicine.
Kathleen Uhl, MD
Dr. Uhl is the Director of the Office of Women's Health (OWH) and Assistant Commissioner for Women's Health at the FDA. Dr. Uhl joined the FDA's Center for Drug Evaluation and Research (CDER) as a medical officer in the Office of Clinical Pharmacology and Biopharmaceutics with subsequent positions in both the Office of Postmarketing Drug Risk Assessment and the Pregnancy and Lactation Labeling Team. She has been an active member of numerous working groups in the FDA for the development of Guidance for Industry and Reviewers, and Proposed Rulemaking. She retains dual faculty appointments as associate professor in Family Medicine and Internal Medicine at the Uniformed Services University in Bethesda, MD and is currently a Captain in the Commissioned Corps of the US Public Health Service. Dr. Uhl is also a loyal member of ASCPT, having held previous appointments on the Society's Board of Directors and Strategic Planning Task Force.
